This invention is directed to an erythropoietin mutein having in vivo biological
activity for causing bone marrow cells to increase production of reticulocytes
and red blood cells, in that the mutein is N-glycosylated at Asn38 and Asn83 but
not N-glycosylated at Asn24. Such muteins have improved pharmaceutical properties.